Robert J. Jr. Marshall Sells 10,000 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Lantheus Price Performance

Lantheus stock opened at $98.85 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $57.92 and a fifty-two week high of $126.89. The firm has a fifty day moving average price of $92.64 and a two-hundred day moving average price of $96.70. The firm has a market cap of $6.77 billion, a price-to-earnings ratio of 16.45 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Institutional Investors Weigh In On Lantheus

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB acquired a new position in Lantheus during the 3rd quarter valued at $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus during the 4th quarter worth about $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus during the fourth quarter valued at about $37,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares during the period. Finally, World Investment Advisors LLC acquired a new stake in Lantheus during the third quarter worth about $60,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial lifted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.